List of Excipients in Branded Drug HECTOROL

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Genzyme Corporation	HECTOROL	doxercalciferol	58468-0123	ALCOHOL
Genzyme Corporation	HECTOROL	doxercalciferol	58468-0123	BUTYLATED HYDROXYTOLUENE
Genzyme Corporation	HECTOROL	doxercalciferol	58468-0123	EDETATE DISODIUM

HECTOROL Excipient Strategy and Commercial Opportunities for Doxercalciferol

Last updated: September 25, 2026

HECTOROL is the brand name for doxercalciferol, a synthetic vitamin D2 analog used to treat secondary hyperparathyroidism in adults with chronic kidney disease. Its commercial opportunity is primarily a generic, formulation-improvement, and hospital-supply opportunity rather than a new-molecule or biosimilar opportunity. The most attractive formulation strategies are low-cost capsule optimization, preservative and container improvements for injectable doxercalciferol, and packaging designed for dialysis-center use.

What is HECTOROL and how is doxercalciferol used?

Doxercalciferol is a prodrug that is metabolized in the liver to 1α,25-dihydroxyvitamin D2. The active metabolite suppresses parathyroid hormone production while supporting calcium and phosphate regulation.

HECTOROL has been marketed in two principal dosage forms:

Product	Active ingredient	Typical strength	Primary use	Commercial channel
HECTOROL capsules	Doxercalciferol	0.5 mg, 1 mg, 2.5 mg	Secondary hyperparathyroidism in chronic kidney disease	Retail, specialty pharmacy
HECTOROL injection	Doxercalciferol	4 mcg/mL	Secondary hyperparathyroidism in dialysis patients	Hospitals, dialysis centers

The capsule and injection products have different excipient and supply-chain requirements. Capsules compete mainly on price, availability, dose flexibility, and pharmacy distribution. Injection products compete on sterility assurance, vial presentation, administration workflow, and purchasing contracts.

The U.S. Food and Drug Administration approved HECTOROL capsules in 1999 and HECTOROL injection in 2000 for secondary hyperparathyroidism associated with chronic renal failure.[1][2]

What excipients are used in HECTOROL formulations?

The oral capsule product uses conventional solid-dose excipients. The injectable product uses a sterile aqueous vehicle with solubilizing and tonicity-control components.

HECTOROL capsule excipients

The HECTOROL capsule formulation has included common oral solid-dose excipients such as:

• Lactose
• Microcrystalline cellulose
• Sodium starch glycolate
• Magnesium stearate
• Gelatin
• Titanium dioxide
• Pharmaceutical colorants

These materials support powder flow, capsule filling, disintegration, lubrication, shell formation, and product identification. None is technically difficult to source. The main development issues are dose uniformity, content uniformity at microgram-to-milligram scale, capsule-shell compatibility, and control of light and oxygen exposure.

Because doxercalciferol is administered at a low dose, blending performance is more important than excipient novelty. A generic manufacturer should prioritize:

1. Geometric dilution or ordered blending.
2. Low-shear mixing that limits segregation.
3. Validated sampling plans for content uniformity.
4. Control of lubricant concentration and blending time.
5. Packaging that limits moisture and light exposure.

Replacing lactose may create a commercial advantage for patients with lactose intolerance, although the clinical and market value must be weighed against development cost. Suitable alternatives include mannitol, anhydrous dibasic calcium phosphate, or spray-dried cellulose systems. Any replacement must preserve dissolution and bioequivalence.

HECTOROL injection excipients

The injectable formulation has used:

• Ethanol as a cosolvent
• Polysorbate 20 as a solubilizer
• Sodium chloride for isotonicity
• Water for injection

The injectable strategy is more demanding because the formulation must satisfy sterility, particulate, extractables, leachables, container-closure, and stability requirements. Polysorbate oxidation and peroxide formation require particular attention. Ethanol content also affects container compatibility, closure performance, and operator handling.

A generic injectable developer should establish:

• Polysorbate peroxide specifications
• Headspace oxygen controls
• Light-protection requirements
• Low-temperature and accelerated stability
• Compatibility with polypropylene syringes and infusion components
• Container-closure integrity through shelf life
• Particulate and subvisible-particle limits
• Administration compatibility with dialysis-center equipment

The formulation may be technically simple, but injectable manufacturing creates a higher barrier than capsule production. A reliable sterile supply chain can support premium pricing relative to a commodity oral product.

What excipient strategy is most attractive for HECTOROL generics?

The highest-probability strategy is a conservative formulation that matches the reference product closely. Novel excipients are unlikely to produce a strong return unless they solve a measurable problem.

Strategy 1: Reference-like capsule formulation

A reference-like capsule is the lowest-risk path for an ANDA. The developer should use established excipients with compendial status and broad regulatory precedent.

The principal value drivers are:

• Low raw-material cost
• High blend uniformity
• Simple manufacturing
• Short scale-up cycle
• Broad contract-manufacturing availability
• Lower risk of formulation-specific regulatory questions

This approach is appropriate for a price-focused generic entrant.

Strategy 2: Lactose-free capsule

A lactose-free version could target patients or institutions seeking to avoid lactose-containing products. Mannitol and microcrystalline cellulose are practical alternatives, but the product must demonstrate comparable dissolution and bioequivalence.

The opportunity is niche. Doxercalciferol is not typically selected because of excipient differentiation, and the capsule dose is small. A lactose-free product may have value in hospital formularies or specialty-pharmacy catalogs, but it is unlikely to support a large price premium without a recognized intolerance or procurement requirement.

Strategy 3: Improved moisture and light protection

A more commercially credible improvement is packaging rather than a new excipient. Options include:

• High-barrier blister packaging
• Aluminum-aluminum blister packs
• Opaque high-density polyethylene bottles
• Desiccant systems
• Unit-dose packaging
• Serialized packaging for dialysis-related distribution

Packaging improvements can extend stability, reduce dispensing errors, and support long-term inventory storage. They also create fewer regulatory complications than introducing a new excipient.

Strategy 4: Injectable polysorbate-control platform

For injection, the most meaningful formulation opportunity is improved control of polysorbate degradation. A developer could use a tighter raw-material specification, lower-peroxide polysorbate, nitrogen overlay, improved vial headspace control, or a container system with lower oxygen transmission.

These changes may reduce subvisible particles and potency loss. They must be validated against the reference product and assessed under ICH stability conditions.[3]

Strategy 5: Ready-to-use institutional presentation

A ready-to-use vial or prefilled syringe could reduce preparation steps in dialysis centers. The opportunity depends on regulatory classification and demonstration of equivalent dose delivery.

Potential advantages include:

• Fewer manipulation steps
• Lower preparation burden
• Reduced dosing errors
• Improved inventory control
• Faster administration
• Better compatibility with institutional medication systems

The main barriers are device development, extractables and leachables, container-closure validation, human-factors work, and a potentially more complex 505(b)(2) or combination-product pathway.

What FDA pathway applies to HECTOROL generic products?

A conventional capsule generic would normally use the ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.

An injectable product with the same active ingredient, strength, dosage form, route, and inactive-ingredient profile may also qualify for an ANDA. A material change in vehicle, delivery system, concentration, or presentation could create additional regulatory requirements.

A 505(b)(2) application may be relevant for:

• A novel injectable vehicle
• A prefilled syringe
• A new administration system
• A different concentration
• A modified-release oral product
• A formulation with clinically meaningful differences from the reference product

FDA generally expects a developer to justify any inactive-ingredient difference, especially for parenteral products. The closer the formulation is to the reference listed drug, the lower the risk of additional clinical or compatibility work.

What patents protect HECTOROL and when does exclusivity expire?

Doxercalciferol is an older small-molecule product. Its principal commercial protection is no longer expected to depend on long-lived new chemical entity exclusivity. The product was approved more than two decades ago, and the practical competitive issues are generic approval, manufacturing capacity, product availability, and contracting.

The relevant protection categories are:

Protection category	HECTOROL relevance	Commercial effect
New chemical entity exclusivity	Historical only	Does not create a current barrier
Composition-of-matter patents	Historical, largely expired for an older product	Limited current protection
Formulation patents	May have existed historically	Must be verified against current Orange Book records
Method-of-use patents	May cover specific CKD or dialysis uses	Relevance depends on listing and enforceability
Regulatory exclusivity	Historical approval-related exclusivity	No expected current blocking period
Manufacturing know-how	Potentially important	Can affect cost, quality, and supply reliability

Current Orange Book entries and patent certifications should be reviewed before filing or acquisition. A generic applicant must assess listed patents, pediatric exclusivity, patent expiration, and any active litigation associated with the reference listed drug.[4]

Because HECTOROL is a small molecule, biosimilar approval is not the relevant competitive pathway. The competitive risk is generic substitution through ANDA approvals.

How strong is the HECTOROL patent estate?

The HECTOROL patent estate is commercially weaker than the estate surrounding a recently launched specialty drug. The product’s age reduces the likelihood that core composition protection remains a meaningful barrier. Any remaining patent value would more likely reside in a specific formulation, dosing method, or delivery configuration rather than in doxercalciferol itself.

A prospective entrant should score the estate across four dimensions:

1. Whether any patent remains listed in the Orange Book.
2. Whether the claims cover the proposed formulation or only a narrow method of use.
3. Whether the patent term extends beyond the expected ANDA approval date.
4. Whether the reference sponsor has a history of enforcing related patents.

An old product can still present litigation risk if a narrow formulation patent remains active. That risk is usually more manageable than a composition patent blocking the entire active ingredient.

Are there Paragraph IV challenges to HECTOROL?

A Paragraph IV certification is relevant if an ANDA applicant asserts that a listed patent is invalid, unenforceable, or not infringed. The commercial effect depends on whether the patent is listed and whether the reference sponsor brings an infringement action within the statutory period.

For HECTOROL, the core generic-entry analysis is likely to focus on:

• Current Orange Book patent listings
• Any unexpired formulation patents
• The proposed generic’s inactive-ingredient profile
• Capsule versus injection product scope
• Patent-term calculations
• Litigation settlements or consent judgments
• Whether any 30-month stay remains available

A Paragraph IV strategy may have limited value if no commercially meaningful patent remains listed. A Paragraph III certification or ordinary patent-expiration approach may be more appropriate where the only relevant patents have expired.

What patent litigation and settlement risks affect HECTOROL?

The most material risks are product-specific rather than platform-wide. A buyer or licensee should examine:

• Prior infringement complaints involving doxercalciferol
• Any consent judgments affecting generic launch
• Supply or licensing agreements involving the reference product
• ANDA approvals with tentative or final status
• Manufacturing-site restrictions
• Settlement terms that limit launch dates or dosage forms

No current litigation or settlement position should be inferred solely from the historical brand name. Litigation status must be tied to the relevant patent numbers, ANDA applicants, dosage form, and court docket.

What commercial opportunities exist for HECTOROL?

Generic oral capsules

The oral capsule market offers the lowest technical barrier. The opportunity is strongest where a supplier can provide:

• Reliable 0.5 mg, 1 mg, and 2.5 mg strengths
• Consistent pharmacy inventory
• Competitive acquisition cost
• Broad wholesaler access
• Low back-order risk
• Unit-dose or blister packaging

The main risk is price erosion. Multiple ANDA approvals can compress margins quickly, particularly when the product has limited clinical differentiation.

Generic injection

The injection has a higher manufacturing barrier and may support better economics. Dialysis centers and hospitals value supply continuity because treatment schedules are recurring and product substitution can require operational changes.

Commercial advantages may include:

• Sterile manufacturing capacity
• Consistent vial supply
• Contract pricing for dialysis networks
• Reduced preparation steps
• Lower particulate and stability risk
• Reliable cold-chain or controlled-room-temperature logistics, as applicable

The main risks are sterile-facility qualification, batch failure, shortage exposure, and institutional contracting pressure.

Contract manufacturing and licensing

A manufacturer with sterile injectable capability could license a doxercalciferol product to a distributor, dialysis supplier, or specialty-pharmacy company. The strongest deal structure would likely combine:

• Territory-specific commercialization rights
• Minimum purchase commitments
• Shared responsibility for FDA maintenance
• Supply guarantees
• Price-adjustment mechanisms for ethanol, polysorbate, vial, and sterile-manufacturing costs
• Back-order and shortage remedies

For capsules, licensing value is lower unless the partner has a strong nephrology distribution network.

How does HECTOROL compare with competing vitamin D analogs?

Product	Active ingredient	Dosage forms	Main commercial distinction
HECTOROL	Doxercalciferol	Capsule, injection	Vitamin D2 analog with oral and dialysis use
ZEMPLAR	Paricalcitol	Capsule, injection	Established vitamin D receptor activator
CALCITRIOL products	Calcitriol	Capsule, solution, injection	Direct active vitamin D metabolite
Generic vitamin D analogs	Various	Product-specific	Price and availability competition

HECTOROL competes with paricalcitol and calcitriol in the management of secondary hyperparathyroidism. Formulary decisions depend on parathyroid hormone control, calcium and phosphate effects, dosing convenience, acquisition cost, and dialysis-provider protocols.

An excipient advantage alone is unlikely to displace an established competitor. A commercial product needs a measurable benefit in supply, administration, stability, packaging, or price.

What generic launch scenarios exist for HECTOROL?

Launch scenario	Product	Investment	Margin potential	Main risk
Conservative ANDA	Capsule	Low to moderate	Low	Rapid price erosion
Institutional generic	Injection vial	Moderate to high	Moderate	Sterile manufacturing and contracts
Reformulated product	Capsule or injection	Moderate	Moderate	Additional FDA requirements
Prefilled syringe	Injection	High	Higher if adopted	Device and regulatory complexity
Licensed supply product	Either	Variable	Depends on contract	Reliance on partner distribution

The most defensible commercial sequence is usually a conventional capsule product followed by an injectable product, provided the sponsor has access to sterile manufacturing and dialysis-center customers.

Key Takeaways

• HECTOROL is doxercalciferol, an older small-molecule vitamin D analog for secondary hyperparathyroidism.
• The main competitive pathway is generic ANDA entry, not biosimilar development.
• Capsule formulation opportunities are limited because the existing excipients are conventional and inexpensive.
• The strongest oral opportunity is supply reliability, dose availability, lactose-free positioning, or improved unit-dose packaging.
• Injectable doxercalciferol offers greater technical differentiation through polysorbate control, oxygen management, vial design, and ready-to-use presentations.
• The commercial value of any remaining patent depends on current Orange Book listings and claim scope.
• Hospital and dialysis-center contracting can provide better economics for injection than for oral capsules.
• A new excipient is unlikely to create meaningful value unless it improves stability, compatibility, tolerability, or administration.

FAQs About HECTOROL Excipient and Commercial Strategy

Is HECTOROL a biologic that requires a biosimilar?

No. HECTOROL contains doxercalciferol, a chemically synthesized small molecule. Competing products would generally use the generic drug approval pathway rather than the biosimilar pathway.

Which HECTOROL dosage form has the higher entry barrier?

The injection has the higher barrier because it requires sterile manufacturing, particulate control, container-closure validation, and injectable stability data. Capsules are easier to manufacture but are more exposed to rapid price competition.

Can a lactose-free HECTOROL capsule support premium pricing?

Potentially, but the opportunity is niche. A lactose-free product would need to demonstrate reliable bioequivalence and a commercial benefit that pharmacies, hospitals, or patients recognize.

Is polysorbate 20 a major technical risk in HECTOROL injection?

It can be. Polysorbate oxidation, peroxide formation, particle generation, and interaction with packaging materials can affect injectable stability. Raw-material controls and oxygen-management procedures are important.

What is the most valuable HECTOROL licensing asset?

A validated sterile injectable product with dependable supply and access to dialysis-center or hospital contracts is likely more valuable than a conventional oral capsule formulation.